Results for second primary malignancies translation from English to Croatian

second primary malignancies
druge primarne maligne bolesti

second primary malignancies (spms)
druge primarne zloćudne bolesti

cancer (second primary malignancies)
rak (druga primarna zloćudna bolest)

an increased incidence of second primary malignancies (spm) has also been observed in patients with newly diagnosed mm receiving lenalidomide.
povećana incidencija drugih primarnih zloćudnih bolesti opažena je također u bolesnika s novodijagnosticiranim multiplim mijelomom koji su primali lenalidomid.

physicians should carefully evaluate patients before and during treatment using standard cancer screening for occurrence of second primary malignancies and institute treatment as indicated.
zbog moguće pojave drugih primarnih malignih bolesti liječnici trebaju, prije i tijekom liječenja, pozorno obraditi bolesnike uporabom standardnih testova probira i prema potrebi započeti liječenje.

second primary malignancies are known to be associated with lenalidomide exposure which was extended in patients treated with empliciti combined with lenalidomide and dexamethasone vs. lenalidomide and dexamethasone.
poznato je da su druge primarne zloćudne bolesti povezane s izlaganjem lenalidomidu, koje je bilo dugotrajnije u bolesnika liječenih lijekom empliciti u kombinaciji s lenalidomidom i deksametazonom nego u onih liječenih lenalidomidom i deksametazonom.

the second primary objective of the study should be the assessment of the compliance with risk minimization recommendations and the controlled access program for patients receiving scenesse.
drugi primarni cilj ispitivanja treba biti ocjena pridržavanja preporuka minimizacije rizika i programa kontroliranog pristupa za bolesnike koji primaju scenesse.

there is an increased risk that paediatric patients with prior malignancies may develop second neoplasm when treated with growth hormone, especially if treatment of the primary malignancy involved radiotherapy.
postoji povećani rizik da pedijatrijski bolesnici s prethodnim zloćudnim bolestima mogu razviti sekundarnu novotvorinu kad se liječe hormonom rasta, osobito ako je liječenje primarne zloćudne bolesti uključivalo radioterapiju.

total skeletal uptake of quadramet in studies of 453 patients with a variety of primary malignancies was 65.5 ± 15.5 % of the administered activity.
ukupna koštana apsorpcija quadrameta u ispitivanjima provedenim na 453 bolesnika s različitim primarnim malignim bolestima, iznosila je 65,5 ± 15,5 % primijenjene radioaktivnosti.

switch to “primary scale” screen via the second “primary line overview” screen (f9 -> f8 -> f7).
izvršite preklapanje na zaslon "primarna vaga" preko drugog zaslona "pregled primarne linije (f9 -> f8 -> f7).

an increase of second primary malignancies (spm) has been observed in clinical trials in previously treated myeloma patients receiving lenalidomide/dexamethasone (3.98 per 100 person-years) compared to controls (1.38 per 100 person-years).
porast drugih primarnih malignih bolesti primijećen je u kliničkim ispitivanjima prethodno liječenih bolesnika s mijelomom koji su primali lenalidomid/deksametazon (3,98 na 100 osoba-godina) u usporedbi s kontrolnim skupinama (1,38 na 100 osoba-godina).